Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Blue-green microalgae (Arthrospira) consumed as a dried whole-food powder; its phycocyanin and protein content have been studied in human trials for effects on blood lipids, glycated haemoglobin and immune markers.
10 of 12 results reported a benefit, from 3 published studies.
3 randomised trials, 53 people
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultImmune overreaction to harmless substances — pollen, dust, food. Causes sneezing, itching, congestion, or skin reactions.
Also known as: Arthrospira platensis, Arthrospira maxima
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Spirulina in allergies.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Be the first to share what you noticed with Spirulina for allergies. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Interleukin-10 (IL-10) levels | reported qualitatively | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Interleukin-1α (IL-1α) levels | reported qualitatively (P < 0.001) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Interleukin-1β (IL-1β) levels | reported qualitatively (P < 0.001) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Interleukin-4 (IL-4) levels | reported qualitatively (P = 0.008) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Nasal obstruction | reported qualitatively (P = 0.039) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Rhinorrhoea prevalence | reported qualitatively (P = 0.021) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Sleep condition, daily working and social activity | reported qualitatively (P < 0.05) | Benefit |
| PMID 32773785 2020 | Randomised trial | 53 | 2 months | Smell reduction | reported qualitatively (P = 0.030) | Benefit |
| PMID 18343939 2008 | Randomised trial | - | - | allergic rhinitis symptoms and physical findings | reported qualitatively (P < 0.001***) | Benefit |
| PMID 15857205 2005 | Randomised trial | - | 12 weeks | IFN-gamma secretion | reported qualitatively | No benefit |
| PMID 15857205 2005 | Randomised trial | - | 12 weeks | IL-2 secretion | reported qualitatively | No benefit |
| PMID 15857205 2005 | Randomised trial | - | 12 weeks | IL-4 levels | 32% | Benefit |